Core Viewpoint - Bioventus Inc. reported strong financial results for Q4 and full-year 2025, highlighting above-market growth, improved margins, and a strengthened balance sheet, while providing optimistic guidance for 2026 [2][20]. Fourth Quarter 2025 Financial Results - Worldwide revenue for Q4 2025 was $157.9 million, a 10.0% increase on an organic basis, driven by double-digit growth in Pain Treatments and Surgical Solutions [3][9]. - Net income attributable to Bioventus was $14.8 million, compared to a net loss of $0.4 million in the prior-year period [4][34]. - Adjusted EBITDA for Q4 was $36.7 million, a 30% increase from $28.3 million in the prior-year period [4]. - GAAP earnings per diluted share improved to $0.21 from $0.00 in the prior-year period, while adjusted EPS was $0.24, slightly down from $0.26 [5]. Full-Year 2025 Financial Results - Total worldwide revenue for 2025 was $568.1 million, a decrease of 0.9% compared to the prior year, primarily due to the divestiture of the Advanced Rehabilitation Business; however, organic revenue grew by 7.5% [6][15]. - Full-year net income attributable to Bioventus was $22.7 million, a significant improvement from a net loss of $36.1 million in the previous year [7][34]. - Adjusted EBITDA for the full year was $116.3 million, up 6.8% from $108.9 million [7]. - GAAP earnings per diluted share for the year were $0.33, compared to a loss of $0.56 in the prior year, while adjusted EPS was $0.68, reflecting a 21.4% increase [8]. Revenue by Business Segment - Pain Treatments generated $79.7 million in Q4, a 15.1% increase, driven by strong demand for hyaluronic acid therapies for knee osteoarthritis [10][15]. - Surgical Solutions revenue was $55.5 million, up 3.4%, attributed to higher U.S. demand for Bone Graft Substitutes [11]. - Restorative Therapies revenue was $22.7 million, reflecting a 26.0% decline due to the divestiture of the Advanced Rehabilitation Business, but showed 10.3% organic growth [11][16]. Geographic Revenue Breakdown - U.S. revenue for Q4 was $139.5 million, a 3.2% increase, with organic growth of 10.1% [13]. - International revenue was $18.4 million, a slight decrease of 0.1%, but increased 9.5% on an organic basis [13][19]. 2026 Financial Guidance - Bioventus expects 2026 revenue between $600 million and $610 million, reflecting growth of approximately 6% to 7% [22]. - Adjusted EPS is projected to be between $0.73 and $0.77, indicating an increase of approximately 7% to 13% [22].

Financial Performance - Third quarter revenue was $139 million, comparable to the prior year, with organic growth of 8%[13, 28] - GAAP net income was $3 million, compared to a net loss of $5 million in the prior year[23, 28, 29] - Adjusted EBITDA increased by 13% to $27 million, with Adjusted EBITDA margin expanding by over 200 basis points[23, 28] - Cash from operations nearly tripled for the quarter and is up 88% year-to-date[23] - Adjusted Gross Margin increased 50 basis points due to improved product mix[37] - Adjusted Net Income nearly tripled due to increased gross margin, decreased operating expenses, and decreased interest expense[44] Segment Performance - Pain Treatments revenue grew by 6% to $67 million, driven by strong Durolane volume growth[30, 31, 36] - Surgical Solutions revenue increased by 9% to $50 million, with growth in Bone Graft Substitutes[32, 33, 36] - Restorative Therapies revenue declined by 29% to $21 million due to the divestiture of the Advanced Rehabilitation Business, but EXOGEN grew by 11%[34, 35, 36] Strategic Initiatives - The Peripheral Nerve Stimulation (PNS) market is estimated at approximately $200 million in the U S, expected to exceed $500 million by 2029, with annual growth above 20%[20] - The company expects PNS and PRP to provide at least 200 basis points of profitable growth in 2026[22] Financial Outlook - The company reaffirmed its 2025 financial guidance, with net sales expected to be in the range of $560 million to $570 million, representing organic growth of 6% to 8%[46] - Adjusted EBITDA is projected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share in the range of $0 64 to $0 68[46]

Second Quarter 2025 Performance - Second quarter revenue reached $148 million, with organic revenue growth of 6%[13] - Adjusted Earnings Per Share (EPS) increased 31% to $0.21, and Adjusted EBITDA margin increased 23%[13] - Surgical Solutions revenue increased 11% compared to the prior year quarter, driven by double-digit growth in Ultrasonics[39] - Restorative Therapies revenue declined 32% compared to the prior year quarter due to the divestiture of the Advanced Rehabilitation Business, while EXOGEN grew 11%[39] - Pain Treatments revenue increased 1% compared to the prior year quarter[39] Financial Metrics and Guidance - Adjusted Gross Margin increased 50 basis points due to improved product mix[40] - The company ended the second quarter with $33 million in cash and $341 million in debt outstanding[48] - Cash from operations was an inflow of $26 million in the second quarter[48] - The company reaffirms its 2025 financial guidance, projecting net sales in the range of $560 million to $570 million, representing organic growth of 6% to 8%[52] - Adjusted EBITDA is expected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is projected to be in the range of $0.64 to $0.68[52] Strategic Initiatives and Future Outlook - The company received FDA 510(k) clearance for StimTrial and TalisMann, Peripheral Nerve Stimulation (PNS) products, targeting the chronic peripheral pain market[18, 20] - The PNS market is estimated to be growing above 20% annually in the U S and is expected to exceed $500 million by 2029, with an expected total addressable market of approximately $2 billion[20] - The company plans to invest in a direct sales force in the second half of 2025 and expects TalisMann and StimTrial to potentially generate $100 million or more of revenue[27] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[30] - The company expects cash from operations in 2025 to nearly double compared to 2024 and expects to reduce net leverage to below 2 5 times by the end of 2025[30, 48]